SW620 and HCT116 cells treated with Arylquin 1 were subjected to Western blot (Figure 4), showing that N-cadherin levels were significantly lower in Arylquin-1-treated CRC cells in a dose-dependent manner, indicating that Arylquin 1 attenuates EMT in CRC. The gene discussed is CDH2; the disease is colorectal carcinoma.